Illumina Array Customers 'Apprehensive' of Possible Roche Takeover, Fear Platform 'Stagnation' | GenomeWeb

By Justin Petrone

Some core laboratory directors and other customers who use Illumina's microarrays are "apprehensive" about Roche's bid to acquire the San Diego vendor for $5.7 billion, arguing that while a Roche takeover might have positive implications for the adoption of next-generation sequencing in the clinic, the Swiss diagnostics giant does not have as strong a reputation when it comes to technology innovation.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PNAS this week: diatom genetic diversity, microfluidic droplet method for single-cell screening, and more.

Scientific publishers are looking into whether artificial intelligence can help the peer-review process, Wired reports.

Researchers are using gene editing to develop more robust livestock and crops, AFP reports.

Researchers rally near the American Association for the Advancement of Science annual meeting in Boston.